Utility estimation of hypothetical chronic obstructive pulmonary disease health states by the general population and health professionals

详细信息    查看全文

• 作者：Sujin Cho (1)
  Hochang Kim (2)
  Seon-Ha Kim (3)
  Minsu Ock (4)
  Yeon-Mok Oh (5)
  Min-Woo Jo (4)
  
  1. Asan Medical Center ; Seoul ; South Korea
  2. University of Ulsan College of Medicine ; Seoul ; South Korea
  3. Department of Nursing ; College of Health Science ; Dankook University ; Cheonan ; South Korea
  4. Department of Preventive Medicine ; University of Ulsan College of Medicine ; 88 ; Olympicro-43gil ; Songpa-gu ; Seoul ; 138-736 ; South Korea
  5. Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases ; Asan Medical Center ; University of Ulsan College of Medicine ; Seoul ; Korea
  
• 关键词：Chronic obstructive pulmonary disease ; Quality of life ; Utility
• 刊名：Health and Quality of Life Outcomes
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：13
• 期：1
• 全文大小：401 KB
• 参考文献：1. Chapman, KR, Mannino, DM, Soriano, JB, Vermeire, PA, Buist, AS, Thun, MJ (2006) Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 27: pp. 188-207 CrossRef
  2. Global initiative for chronic obstructive lung disease, global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. [http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf]
  3. Schlenk, EA, Erlen, JA, Dunbar-Jacob, J, McDowell, J, Engberg, S, Sereika, SM (1998) Health-related quality of life in chronic disorders: a comparison across studies using the MOS SF-36. Qual Life Res 7: pp. 57-65 CrossRef
  4. Testa, MA, Simonson, DC (1996) Assesment of quality-of-life outcomes. N Engl J Med 334: pp. 835-840 CrossRef
  5. Drummond, MF, O鈥橞rien, B, Stodart, G, Torrance, GW (2005) Methods for the economic evaluation of health care programmes. Oxford University Press, London, UK
  6. Torrance, GW, Furlong, W, Feeny, D (2002) Health utility estimation. Expert Rev Pharmacoecon Outcomes Res 2: pp. 99-108 CrossRef
  7. Rutten-van Molken, MP, Hoogendoorn, M, Lamers, LM (2009) Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics 27: pp. 465-477 CrossRef
  8. Oostenbrink, JB, Rutten-van Molken, MP, Monz, BU, FitzGerald, JM (2005) Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 8: pp. 32-46 CrossRef
  9. Sin, DD, Golmohammadi, K, Jacobs, P (2004) Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 116: pp. 325-331 CrossRef
  10. Spencer, M, Briggs, AH, Grossman, RF, Rance, L (2005) Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 23: pp. 619-637 CrossRef
  11. Petrillo, J, Van Nooten, F, Jones, P, Rutten-van Molken, M (2011) Utility estimation in chronic obstructive pulmonary disease: a preference for change?. Pharmacoeconomics 29: pp. 917-932 CrossRef
  12. Ringbaek, T, Brondum, E, Martinez, G, Lange, P (2008) EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients. Respir Med 102: pp. 1563-1567 CrossRef
  13. Harper, R, Brazier, JE, Waterhouse, JC, Walters, SJ, Jones, NM, Howard, P (1997) Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax 52: pp. 879-887 CrossRef
  14. Dandorfer, SW, Rech, J, Manger, B, Schett, G, Englbrecht, M (2012) Differences in the patient鈥檚 and the physician鈥檚 perspective of disease in psoriatic arthritis. Semin Arthritis Rheum 42: pp. 32-41 CrossRef
  15. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease. [http://www.goldcopd.org/]
  16. Attema, AE, Edelaar-Peeters, Y, Versteegh, MM, Stolk, EA (2013) Time trade-off: one methodology, different methods. Eur J Health Econ 14: pp. S53-S64 CrossRef
  17. Torrance, GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5: pp. 1-30 CrossRef
  18. Badia, X, Roset, M, Herdman, M (1999) Inconsistent responses in three preference-elicitation methods for health states. Soc Sci Med 49: pp. 943-950 CrossRef
  19. Altman, DG, Bland, JM (1983) Measurement in Medicine: The Analysis of Method Comparison Studies. J R Stat Soc Ser D (The Statistician) 32: pp. 307-317
  The Third Korea National Health and Nutrition Examination Survey (KNHANESIII).
  20. Torrance, GW, Feeny, D, Furlong, W (2001) Visual analog scales: do they have a role in the measurement of preferences for health states?. Med Decis Making 21: pp. 329-334 CrossRef
  21. Bleichrodt, H, Johannesson, M (1997) An experimental test of a theoretical foundation for rating-scale valuations. Med Decis Making 17: pp. 208-216 CrossRef
  22. Owens, DK, Cardinalli, AB, Nease, RF (1997) Physicians鈥?assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Qual Life Res 6: pp. 77-86 CrossRef
  23. Tsevat, J, Solzan, JG, Kuntz, KM, Ragland, J, Currier, JS, Sell, RL (1996) Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. Med Care 34: pp. 44-57 CrossRef
  24. Rutten-van Molken, MP, Oostenbrink, JB, Tashkin, DP, Burkhart, D, Monz, BU (2006) Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?. Chest 130: pp. 1117-1128 CrossRef
  25. Stahl, E, Lindberg, A, Jansson, SA, Ronmark, E, Svensson, K, Andersson, F (2005) Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 3: pp. 56 CrossRef
  26. Pickard, AS, Wilke, C, Jung, E, Patel, S, Stavem, K, Lee, TA (2008) Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respir Med 102: pp. 519-536 CrossRef
  27. Jones, PW (2009) Health status and the spiral of decline. Copd 6: pp. 59-63 CrossRef
  28. Oostenbrink, JB, Rutten-van Molken, MP (2004) Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 98: pp. 883-891 CrossRef
  29. Andersson, F, Borg, S, Jansson, SA, Jonsson, AC, Ericsson, A, Prutz, C (2002) The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 96: pp. 700-708 CrossRef
  30. Borg, S, Ericsson, A, Wedzicha, J, Gulsvik, A, Lundback, B, Donaldson, GC (2004) A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 7: pp. 153-167 CrossRef
  31. O鈥橰eilly, JF, Williams, AE, Rice, L (2007) Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 61: pp. 1112-1120 CrossRef
  32. Dolan, P, Gudex, C, Kind, P, Williams, A (1996) The time trade-off method: results from a general population study. Health Econ 5: pp. 141-154 CrossRef
  33. Kind, P, Brooks, R, Rabin, R (2005) EQ-5D concepts and method. Springer, Dordrecht CrossRef
  
• 刊物主题：Quality of Life Research; Quality of Life Research;
• 出版者：BioMed Central
• ISSN：1477-7525

文摘

Purpose This study attempted to estimate the utility weights for hypothetical chronic obstructive pulmonary disease (COPD) health states, including the effect of exacerbation, and based on utilities elicited from a representative sample using the time trade-off (TTO). Methods A total of 200 study subjects were recruited using a quota sampling method in Seoul, Korea. Ten COPD health profiles were described reflecting the severity of COPD and the extent of exacerbation. Respondents evaluated each health state using a visual analogue scale and TTO during a personal interview. TTO values were estimated using a linear mixed model, and the model performance was evaluated in terms of its predictive ability and goodness of fit. Results The estimated TTO values were 0.824 in moderate, 0.646 in severe, and 0.305 in very severe COPD health states. The estimated utility decrements in TTO varied from 0.082 for a non-serious exacerbation to 0.228 for one non-serious plus one serious exacerbation per year. The mean absolute error of the TTO model was 0.008, and the generalized R2 was 0.86. Conclusion The social preference of various COPD health states and the utility decrement due to exacerbation can be useful for the economic evaluation of COPD intervention in Korea.